Organization | VieCuri Medical Centre

VieCuri Medical Centre Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Venray Netherlands

Organization Overview

First Clinical Trial

2013

NCT01491711

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

VieCuri Medical Centre | Viecuri Medical Centre Northern Limburg

Active Ingredients

Drugs in Phase 4 Trials (2)

aminolevulinic acid (levulan) (1 trial)

methyl aminolevulinate (metvixia) (1 trial)

Drugs in Phase 3 Trials (1)

levosimendan (1 trial)

Drugs in Other Trials (10)

calcium (1 trial)

flavanol (1 trial)

levetiracetam (keppra) (1 trial)

lorazepam (ativan) (1 trial)

midazolam (versed) (1 trial)

phenytoin (mesantoin) (1 trial)

propofol (diprivan) (1 trial)

thiopental (pentothal) (1 trial)

valproic acid (depakene) (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Kidney Injury (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Basal Cell (Phase 4)

Wounds and Injuries (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 13